Synthesis of some new 1,3,5-trisubstituted pyrazolines with antidepressant and anticonvulsant activities

Journal of Pharmacy of Istanbul University

Volumn 38, Issue 1, 2005, Pages 47-56

  Iyidogan P ^a   Ozdemir Z ^a   Kandilci, B ^a   Gumusel B ^a   Calis U ^a   Bilgin, A A ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Anticonvulsant activity; Antidepressant activity; Pyrazoline; Synthesis

Indexed keywords

1 (4 PHENYLTHIAZOL 2 YL) 3 (2 NAPHTYL) 2 FURYL 2 PYRAZOLINE; 1 (4 PHENYLTHIAZOL 2 YL) 3 (2 NAPHTYL) 5 PHENYL 2 PYRAZOLINE; 1 PHENYL 3 (2 NAPHTYL) 2 FURYL 2 PYRAZOLINE; 1 PHENYL 3 (2 NAPHTYL) 5 PHENYL 2 PYRAZOLINE; 1 THIOCARBAMOYL 3 (2 NAPHTYL) 2 FURYL 2 PYRAZOLINE; 1 THIOCARBAMOYL 3 (2 NAPHTYL) 5 PHENYL 2 PYRAZOLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CHALCONE DERIVATIVE; PYRAZOLINE DERIVATIVE; TRANYLCYPROMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG DETERMINATION; DRUG EFFICACY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ELECTRIC SHOCK; FORCED SWIMMING TEST; MALE; MOUSE; NEUROTOXICITY; NONHUMAN; ROTAROD TEST;

EID: 33744781004     PISSN: 03677524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Parmar, S.S., Pandey, B.R., Dwivedi, C., Harbison, R.D., J. Pharm. Sci., 63,1152-55 (1974).
2. Soni, N., Pande, K., Kalsi, R., Gupta, T.K., Parmar, S.S., Barthwal, J.P., Res. Commun. Chem.Path. and Pharm., 56,129-32 (1987).
3. Bilgin, A.A., Palaska, E., Sunal, R., Arzneim.-Forsch./Drug Res., 43, 1041-44 (1993).
4. Bilgin, A.A.,Yeşilada, A., Palaska, E., Sunal, R., Arzneim.-Forsch./ Drug Res., 42, 1271-73 (1992).
5. Gökhan, N., Yeşilada, A., Ugar, G., Erol, K., Bilgin, A.A., Arch. Pharm. Pharm. Med. Chem., 336, 362-71 (2003).
6. Ruhoǧlu, O., Özdemir, Z., Çaliş, Ü., Gümüşl, B., Bilgin, A.A., Arzneim.-Forsch./Drug Res., 55, 431-436 (2005).
7. Porsolt, R.D., Bertin, A., Jalfre, M., Arch. Int. Pharmacodyn., 229, 327-36 (1977).
8. Schäfer, H., Handbook of Experimental Pharmacology-Antiepileptic Drugs (Eds.:Frey, H.H., Janz, D.), p.199, Springer-Verlag, Berlin(1985).
9. Krall, J. K., Penry, B.G., White, J.H., Kupferberg, E.A., Epilepsia, 9, 409-428 (1978).
10. Wiley, R.H., Jarboe, C.H., Hayes, F.N., Hansbury, E., Nielsen, J.T., Callahan, P.X., Sellars, M.C., J. Org. Chem., 23, 732-38 (1958).
11. Porsolt, R.D., Antidepressants (Eds.: Enna, S.J., Malick, J.B., Richelson, E.), p.121, Raven Press, New York (1981).
12. Willner, P., Mitchell, P.J., Behav. Pharmacol., 13,169-88 (2002).
13. Kostanecki, St.V., Podrajansky L., Ber., 29, 2248-50 (1896).
14. Kaufmann, W.E., Adams, R., J. Am. Chem. Soc., 45, 3029-44 (1923).
15. Weygand, C., Strobelt, F., Ber., 68B, 1839-47 (1935).
16. Emerson, W.S., Patrick, T.M., J. Org. Chem., 14, 790-97 (1949).